Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Ligand Pharmaceuticals (LGND) over the last 11 years, with Q3 2025 value amounting to $1.3 million.

  • Ligand Pharmaceuticals' Amortizatization of Intangibles rose 86956.52% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 22117.65%. This contributed to the annual value of $1.3 million for FY2024, which is 98.63% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Amortizatization of Intangibles is $1.3 million, which was up 86956.52% from $766000.0 recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $1.3 million in Q3 2025 and a low of -$150000.0 during Q1 2021
  • For the 5-year period, Ligand Pharmaceuticals' Amortizatization of Intangibles averaged around $287631.6, with its median value being $157000.0 (2024).
  • In the last 5 years, Ligand Pharmaceuticals' Amortizatization of Intangibles crashed by 8292.68% in 2022 and then surged by 528571.43% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $34000.0 in 2021, then surged by 73.53% to $59000.0 in 2022, then surged by 544.07% to $380000.0 in 2023, then skyrocketed by 59.47% to $606000.0 in 2024, then soared by 120.79% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $766000.0 for Q2 2025, and $839000.0 during Q1 2025.